CYTK: Cytokinetics Incorporated

CYTK新闻

• 07:18 Cytokinetics And The 'Provocative Conversation' That Could Rewrite Heart Disease
• 14:05 Will Camzyos Strengthen BMY's Cardiovascular Portfolio?
• 12:03 Cytokinetics appoints James M. Daly to board of directors and compliance committee
• 12:00 Cytokinetics: Specialty Franchise With Aficamten And Ulacamten (NASDAQ:CYTK)
• 11:42 Cytokinetics appoints James Daly to board of directors
• 20:28 Cytokinetics, Incorporated (CYTK) Q2 2025 Earnings Call Transcript
• 21:10 Cytokinetics (CYTK) Reports Q2 Loss, Tops Revenue Estimates
• 21:09 Cytokinetics shares rise on strong Q2 results
• 20:22 Cytokinetics Inc earnings beat by $0.30, revenue topped estimates
• 11:50 Techne (TECH) Beats Q4 Earnings and Revenue Estimates
• 21:21 Raymond James downgrades Cytokinetics stock rating to Market Perform
• 13:58 Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains?
• 21:40 Cytokinetics (CYTK) CEO Blum sells $190k in stock
• 20:12 Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 21:24 Cytokinetics CEO Robert Blum sells $169,000 in stock
• 11:56 Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
• 15:34 Cytokinetics at Jefferies Conference: Aficamten’s Market Expansion
• 21:08 Cytokinetics to Participate in the Jefferies Global Healthcare Conference
• 11:23 Mizuho cuts Cytokinetics stock target to $84 from $103
• 14:37 Stifel maintains Buy rating and $87 target on Cytokinetics stock
• 13:14 Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence (NYSE:BMY)
• 14:04 Cytokinetics at RBC Conference: Strategic Insights on Drug Development
• 11:16 Tesla’s 2025 Shuffle: Buy the Dip or Dodge the Bullet?
• 12:12 Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress